Close Menu

NEW YORK (GenomeWeb) – Laboratory Corporation of America said today that it plans to acquire Sequenom for $302 million in cash. The deal is expected to close by the end of the year.

Under the terms of the merger agreement, LabCorp will acquire all of Sequenom's outstanding stock for $2.40 per share, or an equity value of $302 million, in a cash tender offer. Including Sequenom's net indebtedness, this represents a total enterprise value of approximately $371 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Pfizer and BioNTech announce they are seeking FDA authorization for their candidate SARS-CoV-2 vaccine.

Science has retracted a 2007 paper from a former Dutch minister and his colleagues, according to Retraction Watch.

The New York Times reports that a plan to cull minks in Denmark to prevent the spread of a new SARS-CoV-2 strain led to calls for the prime minister's resignation.

In Science this week: winner of the Science & SciLifeLab Prize for Young Scientists, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.